Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Australian Prescriber|April 23, 2026
Vitamin B12 deficiency: testing and treatmentDarya Bedz, Cecily Forsyth
Australian Prescriber|January 10, 2022
Non-anaemic iron deficiencyShalini Balendran, Cecily Forsyth
Leukemia & Lymphoma|July 25, 2013
Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyureaEmma Verner, Cecily Forsyth, Andrew Grigg
Leukemia & Lymphoma|August 14, 2023
Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national surveyAlexandra Murton, Cecily Forsyth, David M Ross, et al.
European Heart Journal. Case Reports|August 4, 2021
Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: a case reportPhilopatir Mikhail, James Rogers, Cecily Forsyth, et al.
British Journal of Haematology|August 27, 2010
The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathwayO Giles Best, Nisha Singh, Cecily Forsyth, et al.
Ejhaem|March 24, 2025
Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With RuxolitinibLiesl A Butler, Cecily Forsyth, Claire Harrison, et al.
Leukemia & Lymphoma|December 14, 2011
The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory diseaseO Giles Best, Yiping Che, Nisha Singh, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|April 2, 2014
Perioperative and peripartum prevention of venous thromboembolism in patients with hereditary antithrombin deficiency using recombinant antithrombin therapyMichael J Paidas, Cecily Forsyth, Isabelle Quéré, et al.
Annals of Hematology|February 6, 2017
Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratoryRishu Agarwal, Piers Blombery, Michelle McBean, et al.
Pageof 4